The Diagnostic and Prognostic Value of Presepsin in Sepsis
NCT ID: NCT06180265
Last Updated: 2023-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
90 participants
INTERVENTIONAL
2020-02-01
2023-07-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
No studies compared presepsin to procalcitonin and endotoxin in patients treated with by extracorporeal hemoperfusion with a polymyxin-B-adsorbing cartridge (PMX-HA).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Red Cell Distribution Width Versus Presepsin (Soluble CD14) as a Prognostic Marker in Critically-ill Sepsis Patients
NCT03796715
Procalcitonin in Diagnosis of Sepsis in Critically Ill Patient
NCT04105400
Early Diagnosis and Prognosis of Postoperative Sepsis by Presepsin and Syndecan-1
NCT04718623
Utility of Presepsin in Distinguishing Between Sepsis and SIRS
NCT02052895
CRP Versus PCT as Bio-markers for Sepsis and in Guiding Antibiotics in Critically Ill Patients
NCT04049565
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
No studies compared presepsin to procalcitonin and endotoxin in patients treated with PMX-HA. The investigators aim to evaluate the trend and prognostic value of presepsin versus procalcitonin and endotoxin in ICU patients with septic shock from complicated major abdominal surgery, treated with PMX-HA.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
septic shock patients
Septic shock patients undergoing major abdominal surgery treated with polymyxin-B
presepsin, procalciton, endotoxin
measurement of presepsin, procalciton, endotoxin plasmatic levels
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
presepsin, procalciton, endotoxin
measurement of presepsin, procalciton, endotoxin plasmatic levels
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients undergoing laparoscopic major abdominal surgery
Exclusion Criteria
* organ transplantation,
* palliative care
* metastatic cancer
* head trauma and polytrauma
* coagulopathies
* use of anticoagulants
* neurological disease
* autoimmune disease
* thyroid disease.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Foggia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cotoia Antonella
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ospedali Riuniti
Foggia, Apulia, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
8/C.E./2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.